Good morning and thanks for joining us. Also on the call with me today are Rick Gonzalez, Chairman of the Board and Chief Executive Officer; Rob Michael, President and Chief Operating Officer; Jeff Stewart, Executive Vice President and Chief Commercial Officer; Scott Reents, Executive Vice President and Chief Financial Officer; Carrie Strom, Senior Vice President, AbbVie and President, Global Aesthetics; and Tom Hudson, Senior Vice President, R&D and Chief Scientific Officer. Joining us for the Q&A portion of the call is Roopal Thakkar, Senior Vice President, Development and Regulatory Affairs and Chief Medical Officer. Before we get started, I'll note that some statements we make today may be considered forward-looking statements based on our current expectations. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in our forward-looking statements. Additional information about these risks and uncertainties is included in our SEC filings. AbbVie undertakes no obligation to update these forward-looking statements, except as required by law. On today's conference call, non-GAAP financial measures will be used to help investors understand AbbVie's business performance. These non-GAAP financial measures are reconciled with comparable GAAP financial measures in our earnings release and regulatory filings from today, which can be found on our website. Following our prepared remarks, we'll take your questions. So with that, I'll turn the call over to Rick.

Thank you, Liz. Good morning, everyone, and thank you for joining us today. 2023 is an important year for AbbVie as we experience Humira biosimilar competition in the U.S. market, and as we execute our long-term diversification growth strategy. Now roughly seven months into the year, I'm extremely pleased with the progress that we're making against these objectives. The U.S. Humira biosimilar impact is playing out as projected and slightly better than our planning assumptions. We are competing very effectively with the various biosimilar offerings. We have exceeded our guidance in the second quarter with the overachievement predominantly driven by our growth platform, the base portfolio excluding Humira which, as you know, is the critical driver in our rapid return to growth in 2025 and beyond. To that point, this platform demonstrated operational revenue growth of nearly 8% this quarter with growth expected to further accelerate in the second half of this year. We are also once again raising our full year revenue guidance by $1 billion, which is on top of the $400 million sales increase we delivered in the first quarter for a total overachievement of $1.4 billion. And lastly, we are making good progress with our pipeline across all stages of development, including recent strong data for Skyrizi in ulcerative colitis as well as the recent U.S. approvals for Rinvoq in Crohn's disease and Epkinly in relapsed or refractory DLBCL, both important new therapies for patients. So in summary, I'm extremely pleased with the strong momentum and execution across the business. It reinforces our confidence in our ability to return to robust growth in 2025 with a high single-digit compound annual growth rate to the end of the decade. With that, I'll turn the call over to Rob for additional comments on our business performance. Rob?

Thank you, Rick. AbbVie delivered excellent results once again this quarter. We are demonstrating strong execution across our business with each of our five key therapeutic areas beating expectations. We reported adjusted earnings per share of $2.91, which is $0.11 above our guidance midpoint. Total net revenues were nearly $13.9 billion, more than $350 million ahead of our guidance with the vast majority of the beat coming from our ex-Humira growth platform. In immunology, Skyrizi and Rinvoq are demonstrating impressive growth with sales for both therapies up more than 50% versus the prior year. These two agents have achieved differentiated clinical profiles, including head-to-head data versus Humira and other novel therapies. Skyrizi and Rinvoq are now collectively approved across 10 large indications, and we are forecasting combined revenue growth of more than $3.5 billion this year. With ongoing programs in several additional disease areas, we expect both Skyrizi and Rinvoq to deliver robust growth into the next decade and significantly exceed Humira peak revenue. U.S. Humira is also performing well. The first half erosion came in better than our expectations due to volume. We have been carefully analyzing the biosimilar marketplace, where the total number of competitors has now expanded to eight. While many of these biosimilars have been added to payer formularies, Humira continues to maintain strong parity access. Based on the volume trends and parity access, we now anticipate U.S. Humira erosion of approximately 35%, an improvement of two points versus our original guidance. Neuroscience is another area that is outperforming expectations. Based on the current run rate, this portfolio is now on pace to add more than $1 billion of incremental revenue this year, with continued strong growth from Vraylar as well as our leading migraine portfolio. In aesthetics, the outlook continues to improve. We delivered positive growth this quarter, driven by strong international performance and stabilizing trends in the U.S. These positive trends give us the confidence to once again raise our full year guidance for aesthetics. And as a clear market leader, we are focused on expanding the aesthetics category with increased commercial investment and continued innovation to support robust long-term growth. Given the strong and balanced performance across our diverse portfolio, we are raising our full year adjusted earnings per share guidance by $0.23 and now expect adjusted earnings per share between $10.90 and $11.10. In closing, our operational execution has been outstanding, and we are very well positioned to deliver on our commitments in 2023 and beyond. With that, I'll turn the call over to Jeff for additional comments on our commercial highlights. Jeff?

Thank you, Rob. I'll start with immunology, which delivered total revenues of $6.8 billion, exceeding our expectations. Skyrizi continues to perform exceptionally well. Global sales were approximately $1.9 billion, reflecting very strong operational growth of 51%. Our performance in psoriasis continues to be impressive. Total prescription share in the U.S. biologic market is now at 32%, double the share of the next closest biologic therapy. When you consider that Skyrizi is capturing roughly one out of every two in-play patients, which are either new to therapy or switching, there remains substantial opportunity for continued robust sales growth. And based on the available clinical data we are seeing from emerging competitive therapies in psoriasis, including orals, we feel very confident in Skyrizi's long-term potential with robust sales growth expected through the early part of the next decade. We are also seeing very nice prescription growth in psoriatic arthritis, especially in the U.S. dermatology segment where Skyrizi is approaching the leading new patient biologic market share. Skyrizi's momentum across psoriatic disease is very solid globally as well with total in-play share leadership in nearly 30 key countries. Turning now to IBD, where Skyrizi has demonstrated a very compelling clinical profile, including strong endoscopic data paired with convenient dosing. Uptake in Crohn's disease has been rapid, with total in-play patient share of approximately 25% in the U.S., roughly at parity leadership with Stelara. This uptake is very encouraging for Skyrizi's potential in ulcerative colitis, where we recently reported positive maintenance data with approval and commercialization anticipated next year. Given the momentum we are seeing across all of the approved indications, we will be raising our full year sales outlook for Skyrizi. Moving now to Rinvoq which delivered global sales of $918 million, reflecting operational growth of nearly 57%. A key element of Rinvoq's success is its strong differentiation. It is now approved across seven distinct indications, including four in rheumatology, two in IBD as well as atopic dermatitis. It's the only potent daily oral medication with compelling head-to-head data against multiple novel therapies, including superiority to Humira in RA and Dupixent in AD. It's the only JAK inhibitor now approved to treat both Crohn's disease and ulcerative colitis. And we have established strong and broad commercial access for each of the core diseases with formulary coverage for Crohn's expected to ramp quickly over the next months. As it pertains to Rinvoq's book performance, we are seeing increasing prescriptions across each of the core indications globally, further market share momentum in atopic dermatitis, including now high-teens in-play patient share in the U.S. and robust uptake in IBD, where Rinvoq has demonstrated strong rates of remission and endoscopic improvement. Rinvoq is now capturing roughly one out of every four in-play ulcerative colitis patients in the second line plus setting. And the early data for Crohn's, which launched just in May, also shows a very strong ramp in new patient starts. We remained well positioned for continued momentum in this new indication as the only JAK inhibitor approved to treat Crohn's disease. This level of performance, along with the development of ongoing projects across several other diseases, such as giant cell arteritis and systemic lupus in rheumatology and multiple additional dermatology indications, reinforces the long-term potential for Rinvoq with strong sales growth expected through the early part of the next decade. Global Humira sales were $4 billion, down 24.8% on an operational basis due to biosimilar competition. Erosion in the U.S. remains slightly better than our expectations due to volume with the vast majority of the impact this quarter driven by price. Turning now to hematologic oncology, where total revenues were approaching $1.5 billion. Imbruvica global revenues were $907 million, down 20.8%, consistent with our expectations. Venclexta global sales were $571 million, up 15% on an operational basis with strong demand for both CLL and AML, and we are particularly pleased with the international performance here, following continued reimbursement progress in the EU and inclusion in China's national reimbursement list. We also recently received the U.S. approval for Epkinly in third line plus DLBCL further expanding our on-market portfolio in hem-onc. Early prescription trends have been encouraging, with a more robust opportunity expected as we progress development in earlier lines of therapy. We also anticipate approval and commercialization in Europe and Japan later this year. In neuroscience, revenues were nearly $1.9 billion, up 14.2% on an operational basis. Vraylar continues to exceed our expectations. Sales of $658 million were up 33.9% on an operational basis with increasing momentum across all indications following the MDD approval late last year. Within migraine, we remain the clear market leader with unique treatment options for both acute and chronic conditions. Our oral CGRP portfolio contributed $292 million in combined sales this quarter reflecting growth of more than 30% as we continue to see strong prescription demand for both Ubrelvy and Qulipta. Lastly, total Botox Therapeutic sales were $748 million, up 11.3% on an operational basis, reflecting nice momentum in chronic migraine as well as other approved indications. This franchise continues to outperform our expectations, and we will be raising our full year guidance for the collective neuroscience portfolio. So overall, I'm extremely pleased with the performance and execution across the therapeutic portfolio with growth expected to accelerate through the second half of the year. And with that, I'll turn the call over to Carrie for additional comments on aesthetics. Carrie?

Thank you, Jeff. Second quarter global aesthetics sales were approximately $1.4 billion, up 2.9% on an operational basis with strong performance from our international portfolio offsetting the economic impact in the U.S. U.S. aesthetic sales were $829 million, down 6.2%. Our U.S. portfolio continues to perform well from a competitive perspective. And as expected, the aesthetics markets continued to be impacted by lower consumer spending related to inflationary pressures, which weighed on year-over-year growth rates. U.S. Botox Cosmetic sales were $420 million, a decline of 6.5% versus the prior year. While the U.S. cosmetic toxin market declined low single digits in the second quarter on a year-over-year basis, growth rates improved through the quarter, with June showing a return to positive year-over-year market growth. Botox Cosmetic continues to be the clear market leader, maintaining strong and stable share despite new competitive entrants. U.S. Juvederm sales were $125 million, down 14.5% on a year-over-year basis as we continue to see a more pronounced impact from inflationary dynamics on higher-priced, more deferrable procedures such as filler. The U.S. filler market declined approximately 20% in the quarter on a year-over-year basis due to the persistent inflationary environment. Our Juvederm collection remains market leader and share was stable in the quarter. The economic metrics that we track for the U.S. have largely stabilized. Our consumer market research shows a meaningful recovery from last summer in those intending to get treated with toxins and fillers. Additionally, we have now lapped the beginning of the market downturn, which occurred in the second quarter of last year. Based on these factors, we expect growth rates for the U.S. facial injectables to improve in the second half of this year. Our international aesthetics portfolio continues to perform exceptionally well with strong results in many key markets. Second quarter sales were $555 million, reflecting operational growth of nearly 20%. The International Botox Cosmetic sales of $265 million increased approximately 14% on an operational basis and International Juvederm sales were $243 million, up approximately 28% on an operational basis. Growth in the Asia Pacific region was particularly robust as aesthetic treatment rates in China have fully recovered to pre-COVID levels. We continue to anticipate strong normalized growth through the remainder of the year in China. We are very pleased with the strong performance of our international aesthetics portfolio over the first half of the year and continue to expect similarly strong results in the second half. In the third quarter, we will be facing a challenging year-over-year comparison due to a shipment timing benefit we saw in the third quarter of 2022. This is expected to result in relatively flat growth for our international portfolio in the third quarter. On a full year basis, we expect our international aesthetics sales to grow high single digits. We continue to invest to drive future growth for our aesthetics portfolio with a focus on enhanced promotional activities, improved digital products and services through our Alle platform, sales force expansion, and injector training. We continue to invest in our pipeline as well, and we remain committed to a regular cadence of new product introductions and indication expansions for Botox Cosmetic and Juvederm. We recently announced the FDA approval of SkinVive, the first hyaluronic acid filler in the U.S. for improved skin smoothness of the cheeks, which, along with the recently launched Volux filler for jawline contouring, will help sustain our leadership position in the U.S. filler market. Our investments will allow us to maintain a strong leadership position in the highly underpenetrated and rapidly growing global aesthetics markets. We remain very confident in the long-term outlook for our aesthetics portfolio and continue to expect to deliver greater than $9 billion in 2029. In the near term, the improving aesthetics outlook in the U.S. and continued robust international performance gives us confidence to once again raise our full year aesthetics guidance with an expectation for continued operational growth over the back half of the year. With that, I'll turn the call over to Tom.

Thank you, Carrie. We've continued to make very good progress with our pipeline over the quarter. We had a substantial amount of activity across our R&D pipeline, resulting in new approvals and advancements of several programs. In immunology, we received FDA approval for Rinvoq in Crohn's disease, marking its seventh FDA approval across gastroenterology, rheumatology and dermatology. In our Crohn's development program, Rinvoq demonstrated a very rapid and strong impact on symptoms as well as endoscopic improvement. Given its strong benefit-risk profile, we believe Rinvoq will be an important new medicine for patients suffering from moderate to severe Crohn's disease. While Crohn's disease approval marks the completion of the core indications, we believe Rinvoq has the potential to become a highly effective therapy in several additional important diseases. We recently began Phase III studies for Rinvoq in systemic lupus, hidradenitis suppurativa, and we remain on track to begin Phase III studies in alopecia areata later this year. We'll also see later this year data from a Phase II study in vitiligo, which could support advancement to Phase III in this indication as well. Moving to Skyrizi, where in the quarter, we announced positive topline results from our Phase III maintenance trial in ulcerative colitis. In this study, Skyrizi met the primary and key secondary endpoints at week 52 compared to the withdrawal arm, demonstrating that patients continuing treatment with Skyrizi maintain high levels of clinical remission as well as more stringent endpoints such as endoscopic improvement, histologic endoscopic mucosal improvement and steroid-free remission. It's important to note that approximately 75% of the patients in this study had failed advanced therapy, including not only anti-TNFs, but also other biologics, JAK inhibitors and S1P modulators. This represents a very difficult-to-treat population in ulcerative colitis. Skyrizi's strong performance in patients with and without failure to advanced therapies, including patients who were naive to advanced therapy, demonstrate its utility across the spectrum of moderate to severe UC patients. We remain on track to submit our regulatory applications in the third quarter with approvals anticipated in 2024. We also recently published results from a head-to-head trial comparing Skyrizi to Otezla in patients with moderate psoriasis with Skyrizi demonstrating clear superiority to Otezla on all primary and ranked secondary endpoints at week 16 and 52. At week 52 of this study, 64% of patients achieved absolute skin clearance as measured by PASI 100 and sPGA clear compared to just 3% for Otezla, underscoring Skyrizi's ability to drive very high and durable responses in these moderate patients. In addition to higher clinical efficacy outcomes, the patients treated with Skyrizi, which is a self-injectable administered quarterly, reported improvements in health-related quality of life measures and greater treatment satisfaction compared to those treated with Otezla, which is an oral administered twice daily. Additionally, Skyrizi demonstrated favorable safety and tolerability compared to Otezla. The rates of adverse events, including serious and severe AEs were numerically higher with Otezla than with Skyrizi treatment. Similar to previous studies, Otezla treatment was associated with high rates of gastrointestinal distress such as nausea, diarrhea and vomiting, which resulted in a 7% discontinuation rate in the first 16 weeks of treatment compared to no discontinuations for Skyrizi patients. We're incredibly pleased with these results, which further underscores Skyrizi's position as the best-in-class treatment for moderate-to-severe psoriasis, providing very high efficacy, durable responses, a safe and tolerable profile and convenient quarterly administration. In oncology, we received accelerated approval in the U.S. for Epkinly as a monotherapy treatment for patients with relapsed or refractory DLBCL who had received two or more systemic therapies. We also recently received a positive CHMP opinion with an approval decision in Europe expected later this year. DLBCL is a very aggressive disease where later-line patients have limited options. We're extremely excited to bring this new subcutaneous treatment option to patients. In the quarter, we also announced positive topline results from the follicular lymphoma cohort of a Phase II trial evaluating Epkinly in patients who have received at least two prior lines of therapy. In this study, Epkinly performed very well as a monotherapy, demonstrating an overall response rate of 82%. We are pleased with these results and plan to discuss these data with regulatory agencies about the potential to support a submission for accelerated approval. Beyond the mid-stage studies supporting accelerated approvals in later lines of therapy, we also have Phase III trials ongoing in earlier lines of DLBCL and for follicular lymphoma, and we look forward to providing updates on these programs as the data mature. In our navitoclax program, we recently saw topline results from the Phase III TRANSFORM-1 trial, evaluating navitoclax in combination with ruxolitinib in patients with treatment-naive myelofibrosis. This study met the primary endpoint at week 24, demonstrating a statistically significant improvement in the percentage of patients who achieved spleen volume reduction of at least 35% compared to ruxolitinib plus placebo. For the primary endpoint, the navitoclax combination showed a doubling of improvement over ruxolitinib alone with 63% of patients on the navitoclax combination achieving SVR35 compared to 32% in the ruxolitinib plus placebo combination. In this study, the navitoclax combination did not achieve the first ranked secondary endpoint, which was improvement in total symptom score at week 24. Additional follow-up data on SVR and TSS as well as other endpoints are expected in the fourth quarter of this year. We plan to wait for these more mature data before engaging with regulatory agencies in order to have a more comprehensive picture of the patient's clinical response and clinical benefit that navitoclax can provide. Looking to the remainder of this year, we remain on track for several additional data readouts from our late-stage oncology programs, including Phase III data from Venclexta's CANOVA trial in relapsed/refractory multiple myeloma patients with the t(11;14) mutation. As a reminder, this is an event-driven study, and we're just waiting for a handful of remaining events, so we'd expect to have these data in-house in the coming months. We also remain on track to see Phase II data for Teliso-V in second-line plus advanced non-squamous, non-small cell lung cancer in the fourth quarter. We're also making very good progress with several earlier-stage solid tumor programs. We recently initiated a Phase II study for ABBV-151, our anti-GARP antibody, in hepatocellular carcinoma and plan to begin Phase II in several additional solid tumors over the course of the next 12 months. At the recent ASCO meeting, we presented promising initial results from a Phase I study evaluating our next-generation c-Met ADC, ABBV-400 in several advanced solid tumor types. We're seeing responses across multiple tumors, indicating broad activity. Results in late-line colorectal patients were particularly encouraging, where monotherapy treatment with ABBV-400 resulted in a confirmed overall response rate of 22%, well in excess of standard of care, which is typically less than 2% to 3%. We're also encouraged by the durability of response seen in these early results. These patients had an average of five prior lines of therapy, so this level of efficacy is very encouraging. Based on these results, we plan to start our Phase II program later this year, beginning with a second-line colorectal cancer study. Now moving to neuroscience, where in the quarter, we received a positive CHMP opinion recommending approval of atogepant for migraine prevention. We anticipate a decision in the coming months. If approved, atogepant would be the only oral CGRP antagonist approved in Europe for prevention of both episodic and chronic migraine. This is a debilitating condition that impacts tens of millions of people in Europe, and we look forward to making this new oral treatment option available to patients once approved. Also, in the area of neuroscience, ABBV-916, our A-beta antibody for Alzheimer's disease, is rapidly advancing to dose escalation studies. This antibody is demonstrating a long half-life and very low antidrug antibodies, both important attributes to achieve a best-in-class profile for our A-beta antibody. Dose selection in Phase II is expected to begin early next year. And lastly, in our aesthetics pipeline, we recently submitted our regulatory application for Botox in masseter muscle prominence in China, which is the initial focus for our program given the prevalence of masseter muscle prominence in Asian populations and the significant unmet need for minimally invasive treatment options. In our platysma prominence program for Botox, we remain on track to see data from two additional Phase III studies later this year with our regulatory submission in the U.S. expected near the end of the year. So, in summary, we had a very productive first half of the year across all stages and therapeutic areas of our pipeline, and we look forward to the second half of 2023 with several important clinical and regulatory milestones. With that, I'll turn the call over to Scott.

Thank you, Tom. I'm very pleased with the performance and outlook of the business, including the strong momentum from our ex-Humira growth plan. Starting with our second quarter results, we reported adjusted earnings per share of $2.91, which is $0.11 above our guidance midpoint. These results include a $0.15 unfavorable impact from acquired IP R&D expense. Total net revenues were nearly $13.9 billion, more than $350 million ahead of our guidance and down 4.2% on an operational basis, excluding a 0.7% unfavorable impact from foreign exchange. Importantly, these results reflect high single-digit sales growth from our growth platform. The adjusted operating margin ratio was 47% of sales. This includes adjusted gross margin of 84.7% of sales, adjusted R&D investment of 12.5% of sales, acquired IP R&D expense of 2% of sales and adjusted SG&A expense of 23.2% of sales. Net interest expense was $454 million, the adjusted tax rate was 15.8%. Turning to our financial outlook. We are raising the midpoint of our full year adjusted earnings per share guidance by $0.23 and now expect adjusted earnings per share between $10.90 and $11.10. This guidance does not include an estimate for acquired IP R&D expense that may be incurred beyond the second quarter. We now expect total net revenues of approximately $53.4 billion, an increase of $1 billion. At current rates, we expect foreign exchange to have a modest unfavorable impact on full year sales growth. This guidance includes the following updated assumptions with more than half of the sales improvement attributed to our ex-Humira growth platform. We now expect Skyrizi global sales of approximately $7.6 billion, an increase of $200 million due to continued strong performance across all approved indications. We now expect neuroscience sales of approximately $7.7 billion, an increase of $300 million, reflecting robust prescription growth for Vraylar following the MDD approval as well as better-than-expected performance of Botox Therapeutics and Qulipta. And for aesthetics, we now expect global revenue of approximately $5.4 billion, an increase of $100 million, primarily reflecting momentum from Botox Cosmetic. Lastly, we now anticipate U.S. Humira erosion of approximately 35%, resulting in a sales guidance increase of $400 million based on volume trends and strong parity access. Moving to the P&L. We continue to anticipate adjusted gross margin of 84% of sales and now expect adjusted R&D expense of $6.9 billion, SG&A expense of $12.7 billion and an adjusted operating margin ratio of approximately 46.5% of sales. Turning to the third quarter. We anticipate net revenues of approximately $13.7 billion, which includes U.S. Humira erosion of approximately 40%. And at this time, we expect foreign exchange to have a modest unfavorable impact on sales growth. We expect adjusted earnings per share between $2.80 and $2.90. This guidance does not include acquired IP R&D expense that may be incurred in the quarter. In closing, AbbVie has once again delivered strong top and bottom line performance, and we are very pleased with the momentum of the business heading into the second half of the year. With that, I'll turn the call back over to Liz.

Thanks, Scott. We will now open the call for questions. In the interest of hearing from as many analysts as possible over the remainder of the call, we ask that you please limit your questions to one or two. Operator, we'll take the first question, please.

Vamil Divan, Guggenheim Securities.

So one, I'm just curious: given the strong quarter and the guidance raise, regarding the floor EPS you talked about, do you still see a floor of $10.70 or is it different? And can you say any more at this point about when you expect that floor to occur? My second question is around the IRA, where you have a lot of focus. Do you have any thoughts on what the first list of products around September 1 might include? Are you expecting AbbVie products to be included in that first group of ten? And specifically on Rinvoq, how do you see it potentially being at risk from the IRA, given the significant lifecycle development there? Is there a chance the lifecycle may not be as long, and how are you thinking about prioritizing investment in a small molecule like Rinvoq?

Vamil, this is Rick. I'll take the first question and then maybe Rob and I can also tag team on the first one and the second one as well. So if you look at the floor, if you step back and look at how the business is performing, obviously, the business is performing extremely well. And a significant part of the overachievement is not the Humira business. In fact, of the $1.4 billion we're raising, as Scott said, only $400 million of it is Humira. So $1 billion of it is the growth platform. So all that speaks, we have very strong momentum going into 2024. And we talked before on these calls about, well, when will the trough year occur. And as you think about the floor, I think you have to sort of think about the trough year at the same time. We said in the past that if we significantly overachieved in 2023, that would increase the probability that the trough year was in 2024. And we said that in the backdrop of primarily thinking about it as Humira overachieving. And obviously, now what we're seeing is that it's the majority of the other products that are overachieving the growth platform. So as we look at '24 and as we look at the trough, I think we have to let the year play out a little bit further to see where we're going. But I would say that we're feeling pretty — we're feeling very good about '24. And the growth of that non-Humira business could more than offset the overperformance that we're seeing this year, especially the overperformance that we're seeing on Humira. So it's too early to raise the floor. But what I would tell you is the performance that we're seeing now gives us a tremendous amount of confidence of what '24 looks like.

I'd just add that we've now collectively raised revenue guidance by $1.4 billion, as Rick mentioned. We raised $400 million in the first quarter, $1 billion this quarter. When you look at it, it's really across the key therapeutic areas that will drive long-term growth. We've raised Skyrizi, aesthetics, neuroscience, and also Humira. So we do feel very good about the performance of the business. We've debated when we update the floor; that will come at some point and may not come until we actually give the Q4 guidance on the 2024 call, but as we look at it, the fundamentals of the business are very, very strong, and we're seeing performance across all of the therapeutic areas.

On your second question, IRA. I think it's very difficult to predict. In our planning assumptions, we have assumed for some products to be impacted here early on. Imbruvica is obviously one product that we're looking at carefully. I would say it's right on the bubble of where the cutoff would occur in those first 10 products. So it could be 10, it could be 9, it could be 11, depending upon how some other products. And I say it that way because remember, we're using the data that we have; we're not 100% sure that that is the data that CMS is going to use. So there's not perfect clarity around it. But I would say that's one that we obviously have on the radar screen and we're looking at carefully. Anything you'd add, Rob?

When IRA was passed a year ago, we obviously modeled the impact and we reaffirmed the long-term guidance expectation of high single-digit growth in the second half of this decade. That remains. We looked at what it means in terms of inflation penalties, payer benefit redesign, negotiations. So we did make assumptions around that. I think Rick is correct in that there is still enough uncertainty; we're going to know soon, right? September 1 is when they expect to announce the first list. We have modeled it, but we feel good even with IRA — although it does have an impact and has impacted everyone in the industry — we can still deliver on our long-term growth expectations. On your question — and I think keep in mind, too, when you look at the Medicare percent of business for AbbVie: In the U.S., it's about 20%. Globally, it's a little bit lower, obviously. And so you look at us relative to our peers, we have a lower percent of the business exposed to Medicare. And then when we look at specific Rinvoq, you have to keep in mind with Rinvoq with indication expansion, the percent of sales you're talking about by the time it potentially could be selected for negotiation, potentially in the later part of the decade, you're talking about something like 10% to 12% because if you keep in mind, new indications, in many cases, serve a younger patient population. And so that's the way we're looking at Rinvoq continuing to develop it. We obviously have a number of indications that could launch later in the decade. We feel very good about that. Those indications can collectively contribute a couple of billion dollars of revenue. We'll continue to drive that robust growth we expect from Rinvoq and Skyrizi as well. And so, we've modeled the impact of IRA; we don't expect it to impact the development plans for Rinvoq.

Thank you, Vamil. Operator, next question, please.

Chris Schott, JPMorgan.

Great. Thanks so much. Just two questions for me. I guess first, can you just elaborate in terms of what you're seeing with biosimilar Humira as we think about kind of the price and volume dynamics. I guess specifically, any surprises from your side in terms of how this is playing out? And then just any qualitative comments you can provide about how you see this kind of translating as we kind of think out to 2024? And then my second question was just on the Skyrizi updated guidance. Just a little bit more color on that $7.6 billion at this point, how much is coming from psoriasis versus psoriatic arthritis versus this Crohn's launch that seems to be off to such a strong start. So just directional color of like the mix of the indications would be very helpful. Thank you.

Yeah. Hi, Chris. It's Jeff. And I'll answer your first question. So in a nutshell, we haven't been surprised at any of the dynamics that we've seen play out; we've called it very, very accurately. So again, nothing that's really other than some small volume holding on a little bit better that's really different. So we're quite pleased with how our contracting and access has played out. And that parity access for Humira has been important. And again, it's what we believe would happen. We think it's good for patients, obviously, who can maintain their therapy with very little volatility, and it certainly provided us with a lot of predictability. And so I think we've managed the first half with the Amgen launch and then the second half dynamics very, very well. And if you look to 2024, as I've highlighted before, we do have two-year agreements with some of our accounts. And we negotiated those in good faith, and we expect them to be honored. And remember, these are parity contracts for both 2023 and 2024 with Humira access coexisting with these multiple biosimilars. So I would say based on these dynamics, we're confident that Humira access will remain quite meaningful in 2024. And we know that as more biosimilars become established, we're also, as we've highlighted, appropriately planning for some volume loss in those certain so-called wax-sensitive accounts over time. So really no surprises in terms of what we've seen overall. So we're quite pleased.

Chris, just to give you some color both in terms of the 2023 guidance and the erosion assumptions around that, and then I'll talk about 2024 briefly as well. In the first half of the year, obviously, the vast majority of that erosion came from price. We saw very little volume impact. But now with eight biosimilars on the market and some pursuing a low-act strategy, we have assumed high single-digit volume erosion in the second half of the year, which would put the full year volume impact at mid-single digits. The rest of the 35% comes from prices; we've negotiated those higher rebates and maintained strong parity access. Now while we're not providing 2024 guidance today for U.S. Humira, it is reasonable to assume that there will be additional price erosion. Some will come from the annualization of the rebates that increased in the second half of this year and some will come from rebate increases negotiated for 2024 parity access. I'd also expect more volume erosion in 2024, given the midyear entry of biosimilars this year, especially those that are pursuing a low-act strategy. We've taken a close look at consensus estimates; analyst estimates have a very wide range — the difference between the lowest estimate and the highest estimate approaches $4 billion. However, I'd say the average of those estimates appears to be a reasonable expectation for next year. Obviously, we'll give formal guidance likely on the Q4 call, which is our customary practice. But if you look at the average of those estimates, it should give you a good sense. And then to your question on Skyrizi, of the $200 million, it's split evenly between psoriasis $100 million and IBD $100 million. So that $7.6 billion is about $6.7 billion for psoriasis and around $900 million for IBD.

Thanks, Chris. Operator? Oh, sorry.

Mohit Bansal, Wells Fargo.

Great. Thank you very much for taking my question. And congrats on the quarter. One clarification question and then one question. So clarification: Rick, you mentioned that you think, like, again, at this point, you're not talking about increasing the floor, but you feel comfortable about the floor EPS range of $10.70. Is that fair to be in 2023 or 2024, that's the first clarification question. And then second one is, when we talk to investors, they do feel comfortable about the ex-Humira portfolio. But one question that comes up all the time is the lack of a shiny object or pipeline beyond Skyrizi and Rinvoq. To the extent you agree with that assessment, how do you plan to mitigate that? Or is there anything in the pipeline that investors are missing at this point? Thank you.

Okay. This is Rick. So as far as the $10.70, I would tell you that we feel highly confident in the $10.70. So there shouldn't be any concern there. And as I said, with how the growth platform is performing, we would expect to update at some point the floor. And obviously, by the way I'm saying it, the update would be in an upward direction. So hopefully, that gives some clarity around the floor. When you think about the pipeline, what I tell you about the way we operate is we design our investment in R&D to be able to deliver the kind of growth that we expect for the business over the long term, both short term and long term. Our expectations of the business haven't changed. Our expectations are to build a strategy that allows this business to grow at the top tier and be able to do it over the long term and do it in a consistent way. And I'd say, as I look at our historical performance, we've obviously delivered on that. But as I look at forward-looking performance through the end of this decade and into the early part of the '30s, we're highly confident we can deliver high single-digit growth with the pipeline that we have now, and ultimately, with the assets that we have in the marketplace and how they're performing in the marketplace and their ability to be able to drive significant growth. And you see that in the performance that we're delivering now. If you look at the growth platform's growth in first quarter, and then look at it in the second quarter, it's accelerating at a very good pace, and it will continue to accelerate as we go through the rest of this year. And that once we get to a stable tail or relatively stable tail on Humira will be the growth that emerges to be able to drive the company, and that's what gives us such a high level of confidence. But I think when you look at our pipeline, certainly, we invested significantly in Skyrizi and Rinvoq, and that investment is paying off extremely well. We have a number of assets in our pipeline that will continue to help accelerate that growth as we move forward. So venetoclax for t(11;14) and MDS are examples of that. ABBV-951, we expect to resubmit and get that product on the marketplace. There's a huge need for that product in the marketplace. And a number of other assets, I won't go through every one of them. The rest of our investment in R&D has really been focusing on assets that are designed to be able to sustain our growth from 2030-2040 forward. And so as I look at our pipeline, and I know you don't have as much visibility as we do, but when I look at our pipeline for things like the ABBV-400 platform and the c-Met platform that we have, the data we're seeing in colorectal cancer and non-small cell, that's a significant opportunity for us. ABBV-151 is another significant opportunity for us. Our neuroscience portfolio, ABBV-916 and other assets, is another significant opportunity for us that will emerge in that time frame. We have a next-generation BTK degrader that we're excited about. We have a second-generation BCL-2 that we're very interested in pursuing in multiple myeloma. And so there's a number of assets here that just haven't emerged to the point that you have clear visibility on all that data, but we do have visibility to where they're progressing. And so I think it's just hard for you to assess that earlier pipeline, but it's really designed to deliver on that long-term growth. So we're confident between now and the early '30s. And as that pipeline matures and the data comes out, ABBV-953 is another example of where we have a lot of data now that is demonstrating that it is probably best in class for a bispecific in myeloma. And so as that data emerges, you're going to get more visibility to it. And then obviously, we have the ability to go out and acquire things and we find things that we're interested in.

Okay. Thank you, Mohit. Operator, next question, please.

Terence Flynn, Morgan Stanley.

Maybe a couple for me. Maybe Rick, just to follow up on that last comment, maybe just an update on your M&A/BD appetite here, particularly assets that can contribute more near-term to growth? And then again, I wanted to see what you guys are hearing out there regarding the long-acting Botox competitor. It sounds like you're seeing stable market share, but any feedback on that product?

Okay. So M&A, I mean, obviously, we have a very active group who's constantly working in the area of business development. We're primarily focused in the areas that we operate in franchises. So think of things like immunology, neuroscience, oncology, aesthetics, and eye care would be the key areas of focus. As I said before, we don't need anything to be able to drive that high single digits. Obviously, if we can grow even faster, that's a good thing. I think all of us recognize that. If we find assets that are out there that are later-stage assets, and they fit our strategy and they fit the kind of target product profile that we would expect because we only look for assets that can significantly change standard of care — that's what we're good at. And so we evaluate lots of things, but many of them don't meet that threshold that we're looking for. But if we find something, we would obviously pursue it if it was in an area that we thought we could maximize the value of it. And so, we'll continue to do that. So like I said, I feel good about where we are and what we can drive, and I feel good about how we're looking at assets that are in the outside. We certainly have the financial wherewithal to be able to acquire assets that are out there. And as we've mentioned before, we obviously consider larger assets. And so we continue to look at those. But they have to meet our criteria and they have to be able to deliver a good return to the business. On DAXI, I feel very good about how the team — Harry and the team — are performing against that. But I'll let Carrie actually describe to you how it looks.

Thanks, Rick. So in terms of DAXI, it's been more than six months since their launch and the uptake has been quite limited from our perspective in the low single digits. For context, as we benchmark competitive launches, you would benchmark this launch versus the most recent toxin to enter the U.S. market; you would see it's tracking to about 25% of where another product would be at the same point in its launch. In terms of customer feedback, we continue to hear that expectations are just not being met on duration, both on the customer side and on the consumer side. So we have yet to see impact on Botox share and Botox will continue to be the clear market leader as the other toxins compete for the number two, three, four position in our customers' offices. We are very pleased with the team's ability to execute on these competitive strategies here. And actually, their clear focus not only on the competitive strategies, but also on the broader focus and vision to grow the entire toxin market in the U.S., which we continue to see as the biggest opportunity now and in the future.

Thank you, Carrie. Operator, next question, please.

Evan Seigerman, BMO.

I wanted to just talk about how you think about market share across the growth portfolio, specifically Skyrizi and Rinvoq going forward. Is there a potential ceiling for them in market share you can realize in these markets? Or maybe comment on some of the gating factors for market share growth in each of the patient, provider or reimbursement agreements.

Yes. Evan, it's Jeff. I'll take that one. One of the aspects that we look at very carefully is both in-play capture and overall market share. For example, right now, the in-play capture for Skyrizi in psoriasis is about 50%, so we're capturing one out of every two patients. Our overall market share is about 32% in psoriasis. Theoretically, as we study these markets, if there's not major innovation or major disruption that comes into place — and we really don't see that in psoriasis — you get such a high level of efficacy with Skyrizi that your in-play capture starts to drive up your overall market share over time due to persistency effects and lower fall-off rates. So when you look at that, the market share tends to move toward the in-play capture rate over the long-term planning horizon, though you may not fully get there because other competitors and innovations can alter the landscape. The same concept applies with Rinvoq. For example, it's capturing 25% of second-line-plus in-play share and has a smaller overall market share today. The ability to grow that market share over time is visible in the in-play capture early, and then you see the in-play momentum pull the overall market share up as access and persistency normalize. So that's why we're encouraged by the speed of the ramps and the ability to move market share over time.

The only other thing I would add is with the head-to-head versus Otezla. I would say currently, Skyrizi is not competing much against Otezla, which is a sizable opportunity. We're very pleased with the head-to-head data. That will open up another pool of patients that today Skyrizi doesn't necessarily compete against. So that data will obviously allow us to position it effectively against Otezla.

All right. Thank you. Operator, next question, please.

Chris Raymond, Piper Sandler.

Just maybe a pipeline line of questioning here. Rick, I heard you mention maybe ABBV-951, but it wasn't in your prepared comments. Maybe — I know you guys were saying you're working to respond to the CRL later this year with PDUFA in the first half. Is that still the case? And then maybe also on the pipeline, a couple of quarters ago, I think you guys talked about an interesting combo opportunity in IBD with that GLP-2 in-licensed, I think, from Calibr or Scripps. Any updated thoughts here with this sort of mechanism as a combo agent?

It's Roopal. I can take those. So for ABBV-951, the team is still on track for a resubmission this year, consistent with what you just stated. In fact, we've launched in Japan, and there are already commercial patients receiving it. So the team is very excited about that and we still believe in a very strong profile for that asset. Along the lines of combinations, as you mentioned, on GLP-2, we feel with something like Skyrizi, the data that we've seen in Crohn's and ulcerative colitis still leaves the potential to increase endoscopic or mucosal healing even higher. We're seeing high ranges already, 50% to 60%, but we can potentially go higher and something like a GLP-2 can directly address epithelial repair and mucosal healing, so that could be a potential combination. There are other assets in our immunology pipeline that we are also considering for combination approaches. When you have an asset like Skyrizi and the safety profile that we continue to observe, that creates multiple opportunities for combinations.

If I can just add, we didn't really opt in yet on our collaboration with Calibr, which we expanded this week to more programs. That includes them doing a Phase Ia study which is almost finished. We're going to see the data and make a decision. It does fall into our immunology program, which is in epithelial repair, which Roopal just mentioned. So this is one of the assets which we think if you get a healthy gut to repair, then in combination with immunomodulators you'll get a better response over time. We have another program called RIPK1 which is also involved in epithelial repair. So there are multiple strategies, and this is one where we'll be making a decision and announcing it later this year.

Thank you, Chris. Operator, next question, please.

Steve Scala, TD Cowen.

A couple of questions. This morning, Takeda noted weakness in the U.S. GI market, and it seemed to be mainly on patient levels as opposed to competition. Wondering if you're seeing this and to what do you attribute it? So that's the first question. On the second question, on the Q1 call, the company said it would narrow the EPS range when it had clarity on biosimilar Humira and the landscape for that. So you narrowed that range today despite most biosimilars having been on the market for only three weeks. What do you know now that you didn't know when you reported in April that gives you the confidence to narrow the range today or is it all about the performance of the rest of the portfolio and really not about Humira?

Hi Steve, it's Jeff. No, we don't see any slowdown in the IBD market. This market has been one of the highest growth markets from a CAGR perspective over many, many years. There's such unmet need. So no, we're not seeing any patient slowdown. In our data, we're seeing very fast ramps on in-play share from Skyrizi in Crohn's disease and equally fast ramp in the early weeks from Rinvoq in Crohn's disease. We're capturing up to 25% of the second line plus patients in ulcerative colitis. So I don't know what data Takeda is looking at, but we're seeing that competitors in that space, the leading competitors like Stelara and Entyvio, are under pressure in terms of incremental patient capture since our launches, and we'll continue to monitor. But we don't see any patient flow issues in the marketplace.

Steve, on your second question, it's a combination of both. We're seeing very strong performance from the ex-Humira growth platform, as you can see by the guidance raise; that's really a contributor. But now that we're beyond the middle of the year, we know the biosimilars that have entered the market, we know they're facing prices, and we've maintained strong parity access. So that also increased our confidence which is why we've narrowed the range to $0.20. But it's a combination of both the ex-Humira growth platform performing very strongly as well as where we sit today with biosimilar competition for Humira.

Thanks, Steve. Operator, next question, please.

Carter Gould, Barclays.

Thank you for taking my questions, and congrats on the quarter. I guess, two, acknowledging all your comments on the pipeline and previous comments on BD. Rick, I was looking to get your thoughts on how the more assertive FTC here is limiting your target list on BD or your ability to complete deals? And then maybe just on Botox, I was hoping for a little bit more color on the sustainability of the ex-U.S. trends versus maybe some of that demand getting pushed into the quarter after some of the shutdowns, COVID impacts and whatnot ex-U.S. Thank you.

Okay. So I'll take the first question. Obviously, the FTC appears to be applying a lot more scrutiny to transactions. Having said that, even before this happened, we would always evaluate an acquisition of a product or a company in the backdrop of what we thought the competitive environment would be and our position in that market. So we didn't necessarily go out and try to do transactions that we thought would be extremely difficult from an FTC standpoint. I think the way we think about the FTC situation now is that it may require more time to get acquisitions through; it may even require that you're willing to pursue litigation in order to get those through. But in the end, if your position is that what you're trying to do is not anticompetitive, you will be able to ultimately prevail in that process. I think we're seeing that as some of these transactions go to court in other industries; that's playing out. So I think ultimately, it will end up being more of a delay, but not something that staples your ability to do things that are appropriate to do. That's my perspective on it. Carrie?

Sure. In terms of the aesthetics market internationally, we've been very pleased with the performance so far, and we expect to continue to see that type of strong performance through the rest of the year. We're continuing to invest in key growth markets like Japan and in markets like Brazil. China has become our second biggest market globally. In China, in the first quarter, we did see significant growth as the market was reopening from COVID and some pent-up demand that came through in Q1 and early Q2. Now China has returned to normalized high growth rates. Despite some economic pressures there, we really continue to see strong growth as we continue to invest and expand our promotional footprint through field force, injector training and our consumer efforts. China will continue to be a really attractive market for us. Based on that commercial expansion and also the steady flow of new product launches throughout the decade in that market, we expect continued strong performance. One thing to note is that we do expect Q3 to be relatively flat internationally based on shipment timing from last year, with a return to growth in Q4 and high single-digit growth for the full year internationally.

Thanks, Carter. Operator, next question, please.

David Risinger, Leerink Partners.

Yes. Thanks very much. So I have two questions. Rick, you had mentioned that you're expecting stabilization of Humira sales at some point. Could you provide some perspective on when you might expect that? And then second, with respect to the filler franchise, obviously, it's performing strongly, could you discuss the prospects including the driver of weight loss drug patients seeking to compensate for facial hollowing? Thank you very much.

On the Humira tail, as Rob mentioned earlier, you have the annualization of the impact that we have this year and the second half annualization that's going to roll into 2024. We're going to have further price erosion in 2024, both based on the contracts that we have and how we're expecting the market to play out. The pricing in the marketplace has been consistent with what our original assumptions were. I think the expectation is you'll start to see stabilization of that tail in 2025 and it will become relatively stable in 2026 and beyond. It should still be a substantial tail that we maintain but see less erosion pressure on it at that point.

So, in terms of the filler opportunity and outlook, I'll zoom out a bit: the filler market continues to be really attractive, especially internationally, as you've seen with China driving some strong growth. Our Juvederm brands have become available in China in the past few years and we'll continue to have a cadence of Juvederm launches in China. Our increased investment worldwide continues to drive our filler business and gives us a lot of optimism internationally. In the U.S., inflationary dynamics have impacted the U.S. market for filler more than toxin by the nature of filler pricing and the procedure. Also, patients tend to start on toxin before they add filler, so filler will lag toxin recovery somewhat. We believe the filler market will continue to improve in the second half of the year but will lag toxins. Regarding GLP-1 weight loss drugs like Ozempic, we've been keeping an eye on that and how these weight loss products could impact aesthetics. What we see is anything that gets a consumer engaged in their appearance, including products like Ozempic, is a positive tailwind for the aesthetics business. We are hearing some customers say that facial hollowing resulting from these products is an opportunity for fillers. We see that on social media and are tracking it in other forms of media. We think that, like many other consumer trends around aesthetics, this will be a tailwind and a positive dynamic for the business.

Thanks, David. Operator, next question, please.

Tim Anderson, Wolfe Research.

Thank you. A couple of questions. How much uncertainty is there in terms of contracting in the immunology category in 2024 from a pricing standpoint for Skyrizi and Rinvoq? And when will you be able to provide an update on how those pricing discussions are going for those two brands — not the formal sales guidance, but how the pricing discussions are going. And what is your expectation today for that level of price erosion in 2024 relative to what it's been in 2023?

I'll start and Jeff will add to this. I think there's been some misconception in the marketplace around immunology pricing. This is a market we know well. We've been in it for a long time and we understand the dynamics in detail. We see no fundamental change in the way pricing is being dealt with in this marketplace nor do we expect to see any fundamental change in the foreseeable future. Historically, when we get a new indication or a new product, we evaluate what level of rebating should be done to maximize two things for the product: the speed at which we can drive the ramp and the ultimate peak sales. We weigh those two things against contracting and getting on formulary. So when you get an indication, you make a trade-off. Do you want to be on formulary immediately? If so, you may provide incremental rebates. Is that a financially positive decision for the asset and the company? If it is, we make that decision. Skyrizi and Rinvoq are classic examples of that strategy. Look at how they're performing. We're going to grow those two assets despite increased rebates. That's a good trade-off and we do not see that kind of high single-digit price erosion repeating in 2024.

Maybe to build on Rick's point, consider the fact base — seven indications in one year in one category with one firm. It's unprecedented. When you get a new indication and the sequencing over time, you've got to clear payer P&T committees and those committees don't meet every day; they meet every couple of months. Then you've got to be added to formularies structurally, which often requires replacing a competitor. That's not easy. That's why many competitive firms have to offer free or bridge programs for multiple quarters or years until access ramps. In contrast, on average, we achieved paid access for those seven indications in about 60 days, which is unprecedented. That means minimal free goods and immediate paid access and profit flow and rapid revenue accumulation. So it's a very deliberate strategy and not one we expect to repeat in the same way going forward.

And Tim, on your second question, we said this before: the high single-digit price impact this year is a function of the seven new indications. We do not expect that type of price erosion going forward. It should not be what investors are modeling for 2024.

Thanks, Tim. We have time for one final question.

And that will be from Geoff Meacham, Bank of America.

Great. Good morning, guys. Thanks for taking the question. On OUS Humira, you're obviously well past the initial biosimilar wave, but you're still seeing some sequential decline. So what's the context here? And is there a dynamic that could impact Skyrizi or Rinvoq even indirectly OUS? And then on navitoclax, I know you guys have more details to come, but is there a threshold you're looking for in TRANSFORM-1 to move forward or even to inform development in other indications, just thinking about maybe the tolerability profile and the comparators in that?

If you look at 2023 erosions internationally, about $600 million of the decline is split into three buckets. About $300 million of it is new biosimilar markets — markets like Canada, Puerto Rico, Mexico — those are new waves coming in. So that's the next wave. About $200 million is really the impact of new agents like Skyrizi and Rinvoq where agents that deliver a higher standard of care are taking share, and fortunately, we've brought forward our own products that do that. And then in the international markets, you typically see some low-to-mid single-digit price erosion year-over-year, which accounts for roughly another $100 million. So it's important to characterize the decline correctly: recent biosimilar entry markets, competition from newer agents including our own, and typical international price erosion.

I'll take the navitoclax question. We'll continue to monitor spleen volume reduction as we look toward year-end. If it maintains the high level Tom described, that's definitely positive. Other things we'll look at over a longer term include marrow fibrosis changes and correlations with survival events. We'll get early looks at those. In terms of tolerability, what we've seen thus far is consistent with earlier data and it is a titratable dosing strategy, so clinicians can tailor dosing in the study to individual patient needs. More to come by year-end.

Okay. Thanks, Jeff. And that concludes today's conference call. If you'd like to listen to a replay of the call, please visit our website at investors.abbvie.com. Thanks again for joining us.

As we are concluded. Again, thank you for your participation. You may please disconnect at this time.